Evercore ISI initiated coverage on shares of Arvinas (NASDAQ:ARVN) in a research report sent to investors on Thursday morning, Benzinga’s Daily Ratings Newsletter reports. The brokerage issued an outperform rating on the stock.
Separately, Zacks Investment Research raised shares of Arvinas from a sell rating to a hold rating in a research report on Wednesday, January 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $20.33.
ARVN opened at $21.00 on Thursday. The company has a market cap of $678.93 million and a P/E ratio of -0.83. Arvinas has a 1 year low of $10.19 and a 1 year high of $25.61. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.52 and a quick ratio of 8.52.
In related news, Director Timothy M. Shannon purchased 3,500 shares of the firm’s stock in a transaction on Thursday, March 28th. The stock was purchased at an average price of $14.69 per share, for a total transaction of $51,415.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Ventures Iii L.P. 5Am sold 361,129 shares of the company’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $14.16, for a total value of $5,113,586.64. The disclosure for this sale can be found here.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Deutsche Bank AG purchased a new position in Arvinas in the 4th quarter worth approximately $135,000. Geode Capital Management LLC purchased a new position in Arvinas in the 4th quarter worth approximately $846,000. Diag Capital Management LP purchased a new position in Arvinas in the 4th quarter worth approximately $311,000. Orbimed Advisors LLC boosted its holdings in Arvinas by 1.2% in the 4th quarter. Orbimed Advisors LLC now owns 2,678,810 shares of the company’s stock worth $34,423,000 after acquiring an additional 32,945 shares during the period. Finally, Hillhouse Capital Advisors Ltd. purchased a new position in Arvinas in the 4th quarter worth approximately $8,031,000. Hedge funds and other institutional investors own 41.05% of the company’s stock.
Arvinas Company Profile
Arvinas Holding Company, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer.
Recommended Story: Risk Tolerance and Your Investment Decisions
Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.